Foghorn Therapeutics Inc. (FHTX) Dividend History

Company News

• Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

  Foghorn Therapeutics, a clinical-stage biotechnology company, announced participation in upcoming healthcare conferences and provided an update on its Phase 1 dose escalation trial for FHD-909 targeting SMARCA4 mutated cancers.

  GlobeNewswire Inc.
• Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase

  Optimism is growing in the fight against cancer as researchers make progress, with recent breakthroughs and increased funding for cancer research. Several biotech and biopharma companies have made significant developments in oncology, including Oncolytics Biotech, Nurix Therapeutics, Incyte, Regeneron Pharmaceuticals, and Foghorn Therapeutics.

  Benzinga

  Featured Companies: NRIX ONCY REGN
• Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates

  Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -7.27% and 32.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: CPRX
• Bed Bath and Fox shares drop, Albemarle's stock rallies, and more stocks on the move

  Here are some of the most notable stock movers Monday.

  MarketWatch

  Featured Companies: AI ALB AMPH CARR FOX FOXA FSLR LLY MDT
• Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week

  Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.

  The Motley Fool

  Featured Companies: ALT PGEN